Teva Faces Possible Damages From Selling Generic Protonix

Teva Pharmaceutical Industries may be on the hook for up to $2.1 billion in damages because it sold generic copies of Pfizer's heartburn reliever Protonix before the drug's U.S. patent exclusivity expired in 2011.
Source: WSJ.com: Health - Category: Pharmaceuticals Tags: PAID Source Type: news